Soligenix, Inc. (SNGX)
- Previous Close
0.3830 - Open
0.3764 - Bid --
- Ask --
- Day's Range
0.3764 - 0.3894 - 52 Week Range
0.3700 - 4.2000 - Volume
207,309 - Avg. Volume
2,673,366 - Market Cap (intraday)
5.469M - Beta (5Y Monthly) 1.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7900 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
www.soligenix.comRecent News: SNGX
Performance Overview: SNGX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNGX
Valuation Measures
Market Cap
5.45M
Enterprise Value
503.03k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.16
Enterprise Value/Revenue
1.87
Enterprise Value/EBITDA
-0.06
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.97%
Return on Equity (ttm)
-23,783.76%
Revenue (ttm)
839.36k
Net Income Avi to Common (ttm)
-6.14M
Diluted EPS (ttm)
-0.7900
Balance Sheet and Cash Flow
Total Cash (mrq)
8.45M
Total Debt/Equity (mrq)
138.54%
Levered Free Cash Flow (ttm)
-7.52M